SCHEMBL26565733

SCHEMBL26565733

CCCCCCCCCCOC(CCCCC(=O)O)OCCCCCCCCCC

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FFAR4 Q5NUL3 2/20 0.61
FFAR1 O14842 2/20 0.61
GPR84 Q9NQS5 7/20 0.59
PPARG P37231 7/20 0.59
PPARD Q03181 7/20 0.59
PPARA Q07869 7/20 0.59
HDAC11 Q96DB2 5/20 0.59
TSHR P16473 4/20 0.59
PTPN1 P18031 3/20 0.59
ALDH1A1 P00352 3/20 0.59
TLR2 O60603 2/20 0.59
TDP1 Q9NUW8 2/20 0.59
FABP4 P15090 2/20 0.59
KMT2A Q03164 2/20 0.59
SLC22A6 Q4U2R8 1/20 0.59
SLC22A8 Q8TCC7 1/20 0.59
MEN1 O00255 1/20 0.59
ESR1 P03372 1/20 0.59
ALOX15 P16050 1/20 0.59
PDE4A P27815 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24588598 1.00 FFAR4 (0.61) FFAR4FFAR1GPR84PPARGPPARD
SCHEMBL16829776 1.00 FFAR4 (0.61) FFAR4FFAR1GPR84PPARGPPARD
SCHEMBL24587819 1.00 FFAR4 (0.61) FFAR4FFAR1GPR84PPARGPPARD
SCHEMBL31578784 0.98 FFAR4 (0.58) FFAR4FFAR1GPR84PPARGPPARD
SCHEMBL9626448 0.95 FFAR4 (0.58) FFAR4FFAR1GPR84PPARGPPARD
SCHEMBL22589928 0.89 GPR84 (0.52) FFAR4FFAR1GPR84PPARGPPARD
SCHEMBL16826382 0.89 GPR84 (0.52) FFAR4FFAR1GPR84PPARGPPARD
SCHEMBL22589973 0.89 GPR84 (0.52) FFAR4FFAR1GPR84PPARGPPARD
SCHEMBL20856998 0.89 GPR84 (0.52) FFAR4FFAR1GPR84PPARGPPARD
SCHEMBL30592520 0.89 GPR84 (0.52) FFAR4FFAR1GPR84PPARGPPARD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4262819-A1 NANOMATERIALS COMPRISING ESTER-LINKED ACETALS Beam Therapeutics Inc. (US) 2023-10-25 EP disclosed
US-20230331657-A1 NANOMATERIALS COMPRISING ESTER-LINKED ACETALS BEAM THERAPEUTICS INC. 2023-10-19 US disclosed
US-20230331657-A1 NANOMATERIALS COMPRISING ESTER-LINKED ACETALS BEAM THERAPEUTICS INC. 2023-10-19 US disclosed
US-20230331657-A1 NANOMATERIALS COMPRISING ESTER-LINKED ACETALS BEAM THERAPEUTICS INC. 2023-10-19 US disclosed
CN-116887841-A Nanomaterials comprising ester-linked acetals 比姆医疗股份有限公司 2023-10-13 CN disclosed
WO-2022140252-A1 NANOMATERIALS COMPRISING ESTER-LINKED ACETALS BEAM THERAPEUTICS INC. (US) 2022-06-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230331657-A1 NANOMATERIALS COMPRISING ESTER-LINKED ACETALS LIPA, SGMS1, SGMS2 FFAR4 1230/4885FFAR1 1157/4885GPR84 4577/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.